Nephrogen
Nephrogen is a healthcare company focused on developing curative gene therapies for kidney diseases, particularly polycystic kidney disease (PKD), using advanced CRISPR-Cas genome editing and novel adeno-associated viruses.
Nephrogen Locations
Nephrogen operates from two primary locations in the United States: New York, NY, and Beverly, MA. These locations enable the company to leverage regional resources and collaborate with local medical and research institutions to advance its therapeutic developments.
Nephrogen in the Healthcare Industry
Nephrogen is part of the healthcare sector, specifically focusing on therapeutics. The company is dedicated to developing curative gene therapies, particularly for kidney diseases. Its innovative research targets polycystic kidney disease (PKD), and it aims to provide a significant medical breakthrough in this domain.
Nephrogen Y Combinator S20 Batch
Nephrogen participated in the Y Combinator S20 batch, which provided the company with essential resources and guidance to accelerate its growth. This involvement highlights Nephrogen's commitment to innovation and cutting-edge technology in developing effective therapies for kidney diseases.
Gene Therapies for Kidney Diseases
Nephrogen is pioneering gene therapies to combat kidney diseases, with a particular focus on polycystic kidney disease (PKD). Utilizing CRISPR-Cas genome editing and advanced nucleic delivery methods, such as adeno-associated viruses (AAVs), Nephrogen aims to provide curative treatments. The company has developed a non-invasive method for delivering gene therapy directly to the kidney, employing novel AAV viruses with significantly higher targeting efficiency.
Innovations in Drug Discovery
Nephrogen's drug discovery platform leverages sophisticated tools in computer vision and high-throughput screening (HTS) to identify new small molecule drugs for cystic kidney diseases, including nephronophthisis. This innovative approach allows the company to explore numerous gene targets within the PKD1 gene, which are linked to autosomal dominant polycystic kidney disease (ADPKD).